Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
A new study published in the journal Nature Medicine in February 2020 reports that the administration of neutralizing antibodies against HIV improve the recipient’s specific T cell responses against ...
Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...
Antibodies that specifically bind a protein upregulated in leukemia effectively treat cancer. Researchers now present new insights into how antibody types impact the potency and safety of such ...
Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be ...
Scientists compared the blood of nearly 300 individuals with type 1 diabetes to healthy controls, they found that a higher level of antibodies against gentamicin was associated with increased risk of ...
University of North Carolina School of Medicine. "Antibodies reverse type 1 diabetes in new immunotherapy animal study." ScienceDaily. ScienceDaily, 6 July 2012. <www.sciencedaily.com / releases / ...
Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers ...
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback